We acknowledge that no direct clinical evidence currently supports translating APOE/PLTP/cholesterol ester pathway manipulation to reduce AD risk, but our findings and existing preclinical-clinical bridges provide a credible rationale for this potential. Here, PLTP is linked to Alzheimer disease.